PCV2 Antigen Vaccine for Sub-clinical Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines do not effectively address sub-clinical porcine circovirus type 2 (PCV2) infections in pigs, which can lead to significant growth impairment and unknown economical impacts, as they fail to confer immunity in sub-clinically infected animals and improve growth performance.
Innovation Solution
Administration of a therapeutically effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen to sub-clinically infected animals, characterized by viral loads below 10^6 genomic copies/ml serum, low morbidity, and prolonged virus persistence, to reduce growth impairment and viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines are administered to sub-clinically infected animals, then the vaccination process is completed, but the vaccines fail to confer immunity and improve growth performance
Solution Approach 1:
The vaccine is administered at a specific early time point (e.g., 3-5 weeks of age) before the sub-clinical infection progresses to clinical disease, establishing immunity proactively when the animal is still asymptomatic but vulnerable, thereby preventing growth impairment before it occurs
Solution Approach 2:
The invention changes the timing parameter of vaccination from conventional schedules to specific early post-weaning time points, and adjusts the vaccine formulation parameters to achieve therapeutic efficacy in sub-clinically infected animals, thereby resolving the contradiction between vaccine administration and growth performance improvement
2Ease of operation
If sub-clinical PCV2 infections are present in animals, then the animals remain asymptomatic with low morbidity, but significant growth impairment and viral persistence occur
Solution Approach 1:
The vaccine is administered during the sub-clinical phase of infection when animals are still asymptomatic, taking preliminary action to eliminate the virus before it causes clinical disease and severe growth impairment, thereby maintaining both clinical health and growth performance
Solution Approach 2:
The invention converts the sub-clinical infection state, which is normally harmless and asymptomatic, into a therapeutic opportunity by administering the vaccine during this window, transforming the hidden viral persistence into a treatable condition that can be eliminated before causing harm
Data Source
AI summary
The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.